You probably think of virtual consults for skin issues as a simple win. Members get a quick diagnosis, a prescription in 24 hours, and you save a few bucks compared to an in-person specialist visit. But if you look under the hood of your benefits systems, something unsettling emerges. Most telederm platforms are quietly sabotaging your plan data, sending pharmacy costs through a secret pipeline, and even creating liability risks nobody flagged during the RFP.
It’s not that the clinical care is bad. It’s that the way these platforms connect-or rather, fail to connect-to your administrative ecosystem turns a promising benefit into a data black hole.
The Photograph That Tells You Nothing
A standard doctor visit produces clean, structured data: a CPT code, an ICD-10 diagnosis, a provider NPI. That data feeds your analytics, your stop-loss reporting, your population health models. It’s how you know what’s happening across your plan.
Now imagine a telederm visit. A member takes three photos of a rash. The platform’s AI, or a board-certified dermatologist, reviews the images. They identify a suspicious mole and recommend an urgent biopsy. But what does your claims system see? Just a generic code for "virtual check-in." That’s it.
The platform knows the member is at risk. But your analytics, your care management team, even your stop-loss carrier-they all remain blind. The critical data point-"this patient may have melanoma"-never gets recorded in the systems that matter. That’s the pixel-versus-code conflict. You’re paying for high-quality image analysis, but your admin system only captures a low-resolution data point.
The Pharmacy Pipeline Nobody Audits
Here’s where it gets painful for your bottom line. Many telederm platforms don’t just diagnose-they dispense. They partner with their own mail-order pharmacy, ship branded topical creams at full retail, and never touch your employer’s PBM contract.
Let me give you a concrete example. Suppose you’ve negotiated a steep discount on generic tretinoin through your PBM. The telederm platform bypasses that entirely. It prescribes a branded formulation, fills it through its own pharmacy, and the claim never appears in your pharmacy data. You end up paying twice: once for the telehealth visit, and once for the drug at a markup through a non-network channel.
This is a shadow pharmacy network. It undermines your PBM contract and inflates costs in ways your standard reports can’t detect. And it’s rarely addressed in vendor due diligence.
Licensure Liabilities Hiding in Plain Sight
Consider this: a dermatologist licensed in Texas treats one of your members who’s vacationing in Florida. The platform auto-assigns the doctor. The claim is filed with the Texas doctor’s NPI and a telehealth place-of-service code. But Florida law requires that doctor to be licensed in Florida for prescribing. Was that checked? Often, no.
Your credentialing system has no direct integration with the telederm vendor’s provider panel. If that claim is ever audited-say, during an ERISA lawsuit or a subrogation case-you have zero way to prove the rendering doctor was legally authorized. That’s a benefit administration liability that catches employers off guard.
The Actuary’s Nightmare
Now think about the data your actuaries rely on. Telederm platforms generate episodic, low-diagnosis-specific claims. A member with severe psoriasis uses the app for quick flares. The platform’s AI codes it as “mild plaque psoriasis” instead of the more complex “psoriasis with arthropathy.” Later, that member needs a $100,000 biologic infusion.
Your stop-loss carrier reviews the claims history. They see a pattern of cheap virtual visits with low-severity codes. They may deny the big claim as an “unexpected deterioration” or hike your rates because the risk data looks inconsistent. The problem isn’t the clinical care-it’s the data pollution that makes your plan look healthier than it really is.
What to Actually Do About It
Stop evaluating teledermatology on member satisfaction scores. Start evaluating on data interoperability. Here’s what to demand in your next vendor RFP:
- Require a structured data feed. Don’t accept a basic EDI claim file. Ask for an API that delivers image metadata, provider licenses at time of consult, referral paths (e.g., “required in-person biopsy within 7 days”), and NDC codes for any drug dispensed directly by the vendor.
- Force pharmacy integration. Do not let the vendor use its own pharmacy. Route all prescriptions through your primary PBM. This closes the shadow leak and lets you audit drug costs properly.
- Audit diagnosis fidelity annually. Pull a sample of members with high-cost claims (biologics, Mohs surgery) who also used the telederm benefit. Check whether the platform’s initial diagnosis matches the specialist’s final diagnosis. If the mismatch rate exceeds 5%, your stop-loss credibility is eroding.
Virtual dermatology is a clinical win-I won’t argue that. But from a benefits systems perspective, it’s a data pollution event. The industry needs to stop glorifying convenience and start demanding fidelity: fidelity of data, fidelity of prescribing, and fidelity of reporting. Otherwise, you’re buying a feature that looks good on paper but quietly undermines your plan.